Publications [#98476] of John H Sampson

Papers Published

1. JH Sampson, DA Reardon, AH Friedman, HS Friedman, RE Coleman, RE McLendon, I Pastan, DD Bigner, Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study., Neuro-oncology, United States, vol. 7 no. 1 (January, 2005), pp. 90-6, ISSN 1522-8517
   (last updated on 2006/06/06)

   Abstract:
   Glioblastoma multiforme remains refractory to conventional therapy, and novel therapeutic modalities are desperately needed. TP-38 is a recombinant chimeric protein containing a genetically engineered form of the cytotoxic Pseudomonas exotoxin fused to transforming growth factor (TGF)-alpha. TGF-alpha binds with high affinity to the epidermal growth factor receptor, which is uniformly overexpressed in malignant gliomas, often because of gene amplification. Prior to therapy with TP-38, the patient described here was completely refractory to multiple other therapies, with radiographic and pathologic evidence of tumor progression. After therapy, she improved clinically, was weaned off steroids and anti-convulsants, and experienced a progressive decrease in enhancing tumor volume. Despite multiple prior recurrences, she has not progressed for >43 months after TP-38 therapy. Small remaining areas of enhancement demonstrate no evidence of tumor histologically and are hypometabolic on positron emission tomography. This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38.

   Keywords:
   Brain Neoplasms • Exotoxins • Female • Glioblastoma • Humans • Injections, Intraventricular • Magnetic Resonance Imaging • Middle Aged • Pseudomonas aeruginosa • Recombinant Fusion Proteins • Transforming Growth Factor alpha • Treatment Outcome • administration & dosage* • drug therapy* • pathology